Infliximab 10 mg/kg every 3 weeks for crohn's disease

American Journal of Gastroenterology

Volumn 105, Issue 11, 2010, Pages 2509-2510

  Pillot, Claire ^a   Chevaux, Jean Baptiste ^a   Bigard, Marc André ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; STEROID;

ABDOMINAL PAIN; ADULT; BACTERIAL INFECTION; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; PHARYNGITIS; PRIORITY JOURNAL; SYMPTOM;

ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; HUMANS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78149236864     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.244     Document Type: Letter

References (4)

1. Clark M , Colombel JF , Feagan BC et al. AmericanGastroenterological Association consensusdevelopment conference on the use of biologicsin the treatment of inflammatory bowel disease.Gastroenterology 2007 ; 133 : 312-39.
2. Gisbert JP , Panes J. Loss of response andrequirement of infliximab dose intensificationin Crohn's disease: a review. Am J Gastroenterol2009 ; 104 : 760-7.
3. Regueiro M , Siemanowski B , Kip K et al. infli ximabdose intensification in Crohn's disease. inflammBowel Dis 2007 ; 13 : 1093-9.
4. Rahier JF , Ben-Horin S , Chowers Y et al. Europeanevidence based consensus on the prevention,diagnosis and management of opportunisticinfections in inflammatory bowel disease.J Crohn's Colitis 2009 ; 3 : 7-91